Parameterising User Uptake in Economic Evaluations: The role of discrete choice experiments

Health Economics (United Kingdom)

Volumn 25, Issue , 2016, Pages 116-123

  Terris Prestholt, Fern ^a   Quaife, Matthew ^a   Vickerman, Peter ^a,b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

discrete choice experiments; economic evaluation; low income and middle income country; mathematical modelling; uptake; user preferences

Indexed keywords

ARTICLE; CALCULATION; CONDOM USE; COST EFFECTIVENESS ANALYSIS; DISCRETE CHOICE EXPERIMENT; ECONOMIC EVALUATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; POPULATION RESEARCH; PREDICTION; PREGNANCY; PRIORITY JOURNAL; SAFE SEX; SOUTH AFRICA; THEORETICAL MODEL; CONSUMER ATTITUDE; COST BENEFIT ANALYSIS; DECISION MAKING; ECONOMIC MODEL; ECONOMICS; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH SERVICES RESEARCH; HUMAN; PROCEDURES;

CHOICE BEHAVIOR; CONSUMER BEHAVIOR; COST-BENEFIT ANALYSIS; DECISION MAKING; ECONOMICS, MEDICAL; HEALTH CARE COSTS; HEALTH SERVICES RESEARCH; HUMANS; MODELS, ECONOMIC; SOUTH AFRICA;

EID: 84956582449     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.3297     Document Type: Article

References (28)

1. Aigbogun NW, Hawker JI, Stewart A,. 2015. Interventions to increase influenza vaccination rates in children with high-risk conditions-A systematic review. Vaccine 33: 759-770.
2. Blomquist G, Whitehead J,. 1998. Resource quality information and validity of willingness to pay in contingent valuation. Resource and Energy Economics 20: 179-196.
3. Cremin I, Alsallaq R, Dybul M, et al., 2013. The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis. AIDS 27: 447-58.
4. De Bekker-Grob EW, Hol L, Donkers B, et al., 2010. Labeled versus unlabeled discrete choice experiments in health economics: An application to colorectal cancer screening. Value in Health 13: 315-323.
5. Desrochers RE, Siekmans K, Berti PR, et al., 2014. Effectiveness of post-campaign, door-to-door, hang-up, and communication interventions to increase long-lasting, insecticidal bed net utilization in Togo (2011-2012): a cluster randomized, control trial. Malaria Journal 13: 260.
6. Dimitrov DT, Boily MC, Baggaley RF, et al., 2011. Modeling the gender-specific impact of vaginal microbicides on HIV transmission. Journal of Theoretical Biology 288: 9-20.
7. Fujiwara D, Campbell R,. 2011. Valuation Techniques for Social Cost Benefit Analysis: Stated preference, revealed preference and subjective well-being approaches. London. HM Treasury.
8. Gomez GB, Borquez A, Caceres CF, et al., 2012. The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study. PLoS Medicine 9: e1001323.
9. Gray RT, Ghaus MH, Hoare A, et al., 2011. Expected epidemiological impact of the introduction of a partially effective HIV vaccine among men who have sex with men in Australia. Vaccine 29: 6125-6129.
10. Groom B, Kontoleon A, Swanson TM,. 2004. Environmental resource information and the validity of non-use values: the case of remote mountain lakes. In Econometrics Informing Natural Resources Management, Koundouri P, (ed.), Cheltenham. E. Elgar.
11. Karim QA, Karim SS, Frohlich JA, et al., 2010. Effectiveness and safety of Tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science Epub http://www.sciencemag.org/cgi/content/abstract/science.1193748v1.
12. Kesternich I, Heiss F, Mcfadden D, et al., 2013. Suit the action to the word, the word to the action: Hypothetical choices and real decisions in Medicare Part D. Journal of Health Economics 32: 1313-1324.
13. Krucien N, Gafni A, Pelletier-Fleury N,. 2014. Empirical testing of the external validity of a discrete choice experiment to determine preferred treatment option: The case of sleep apnea. Health Economics. 24: 951-965.
14. Lambooij MS, Harmsen IA, Veldwijk J, et al., 2015. Consistency between stated and revealed preferences: a discrete choice experiment and a behavioural experiment on vaccination behaviour compared. BMC Medical Research Methodology 15: 19.
15. Lancsar E, Swait J,. 2014. Reconceptualising the external validity of discrete choice experiments. PharmacoEconomics. 32: 951-965.
16. Mark TL, Swait J,. 2004. Using stated preference and revealed preference modeling to evaluate prescribing decisions. Health Economics 13: 563-573.
17. Pinkerton S, Abramson P,. 1997. Effectiveness of condoms in preventing HIV transmission. Social Science and Medicine 44: 1303-1312.
18. Pinkerton S, Abramson P, Turk M,. 1998. Updated estimates of condom effectiveness. Journal of the Association of Nurses in AIDS Care 9: 88-89.
19. Ryan M, Watson V,. 2009. Comparing welfare estimates from payment card contingent valuation and discrete choice experiments. Health Economics 18: 389-401.
20. Salampessy BH, Veldwijk J, Jantine Schuit A, et al., 2015. The predictive value of discrete choice experiments in public health: An exploratory application. Patient 8: 521-529.
21. Terris-Prestholt F, Foss AM, Cox AP, et al., 2014. Cost-effectiveness of tenofovir gel in urban South Africa: Model projections of HIV impact and threshold product prices. BMC Infectious Diseases 14: 14.
22. Terris-Prestholt F, Hanson K, Macphail C, et al., 2013. How much demand for new HIV prevention technologies can we really expect? Results from a discrete choice experiment in South Africa. PLoS One 8: e83193.
23. Thirumurthy H, Masters SH, Rao S, et al., 2014. Effect of providing conditional economic compensation on uptake of voluntary medical male circumcision in Kenya: a randomized clinical trial. JAMA 312: 703-11.
24. Underhill K,. 2013. Study designs for identifying risk compensation behavior among users of biomedical HIV prevention technologies: balancing methodological rigor and research ethics. Social Science and Medicine 94: 115-23.
25. Verguet S, Stalcup M, Walsh JA,. 2013. Where to deploy pre-exposure prophylaxis (PrEP) in sub-Saharan Africa? Sexually Transmitted Infections 89: 628-34.
26. Verguet S, Walsh JA,. 2010. Vaginal microbicides save money: a model of cost-effectiveness in South Africa and the USA. Sexually Transmitted Infections 86: 212-6.
27. Walensky RP, Park JE, Wood R, et al., 2012. The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clinical Infectious Diseases 54: 1504-13.
28. Williams BG, Karim SSA, Karim QA, et al., 2011. Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa. Journal of Acquired Immune Deficiency Syndromes 58: 207-10.